Ann S. LaCasce

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elı́as Campo, Elaine S. Jaffe, James R. Cook et al. · Blood · 2022 · 1.5K citations · Full text

Veterinary Medicine, Hematology, Oncology +17

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text

Life Sciences, Immunology, Oncology +17

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Zheng Zhou, Laurie H. Sehn, Alfred Rademaker et al. · Blood · 2013 · 953 citations

Medicine, Hematology, Oncology +14

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 739 citations · Full text

Medicine, Oncology, Pharmacology +10